Internal Medicine Doctors in Fort Washington, MD Accepting Medicare

9 Internal Medicine doctors found. Showing 1 - 9

Elizabeth Park Tanner, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 E Swan Creek Rd, Fort Washington, MD 20744 Phone: 301-373-7900    Fax: 301-373-6900

Thomas P Gage, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 12400 Hatton Point Rd, Fort Washington, MD 20744 Phone: 301-292-6239

Dr. Deidra L. Varner, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11701 Livingston Rd, Suite 203, Fort Washington, MD 20744 Phone: 301-292-7270    Fax: 301-203-0740

Dr. Amir Mirzaalikhani, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 11711 Livingston Rd, Fort Washington, MD 20744 Phone: 301-203-2232

Dr. Samuel Kleiman, M.D. Internal Medicine - Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 11711 Livingston Rd, Fort Washington, MD 20744 Phone: 301-203-2232

Dr. Frank M. Ryan, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 11701 Livingston Rd, Suite 103, Fort Washington, MD 20744 Phone: 301-292-7270    Fax: 301-203-0740

Jose Luis Puebla-tarilonte, M.D. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 12004 Autumnwood Ln, Fort Washington, MD 20744 Phone: 301-203-1543

Dr. Syed Haris Ahmed Pir, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11711 Livingston Rd, Fort Washington, MD 20744 Phone: 301-292-7000

Dr. Lalitha Vedantam, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 E Swan Creek Rd, Fort Washington, MD 20744 Phone: 301-292-7270    Fax: 301-203-0740

News Archive

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

New class of molecules capable of blocking formation of tau protein fibrils

A new class of molecules capable of blocking the formation of specific protein clumps that are believed to contribute to Alzheimer's disease pathology has been discovered by researchers at the University of Pennsylvania School of Medicine. By assaying close to 300,000 compounds, they have identified drug-like inhibitors of AD tau protein clumping, as reported in the journal Biochemistry.

Donor governments need to conduct more post-market oversight of generic medicines

The WHO and FDA approve drugs to treat malaria, tuberculosis and other diseases in low- and middle-income countries, but "some of the manufacturers, predominantly Chinese and Indian firms, may be knowingly producing" poor quality medicines, according to "the conclusion of my research teams' studies, published this week in the journal Research and Reports in Tropical Medicine," Roger Bate, resident scholar with the American Enterprise Institute and lead author of the studies, writes in a Washington Post opinion piece.

FDA approves new gene therapy targeting rare form of inherited vision loss

The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness.

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

A new study has found that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later.

Read more Medical News

› Verified 2 days ago